Skip to main navigation Skip to search Skip to main content

NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab

  • NSABP FC-6 Study Group

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry